Pfizer (NYSE:PFE) Shares Down 1.1% - Time to Sell?

Key Points

• Pfizer shares fell 1.1% to about $27.81, while trading volume was below average. Analysts’ consensus rating remains “Hold,” with an average price target of $28.39.
• Pfizer reported promising pipeline developments, including positive Phase 3 vitiligo results for LITFULO, a successful Phase 2 atopic dermatitis study for tilrekimig, and progress in a breast-cancer trial.
• The company remains in transition amid declining COVID-related sales, patent-loss pressure and a Florida lawsuit over vaccine disclosures. Its roughly 6% dividend yield may appeal to income investors, but future performance depends on pipeline launches and acquisitions.

Pfizer Inc. (NYSE:PFE - Get Free Report) dropped 1.1% on Friday. The stock traded as low as $27.44 and last traded at $27.8080. Approximately 34,908,008 shares were traded during mid-day trading, a decline of 14% from the average daily volume of 40,713,457 shares. The stock had previously closed at $28.12.

Key Pfizer News

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: LITFULO delivers positive Phase 3 vitiligo results: Pfizer said its oral treatment ritlecitinib significantly improved facial and total-body repigmentation versus placebo in the TRANQUILLO and TRANQUILLO 2 Phase 3 trials. Positive patient-reported outcomes and the potential to expand LITFULO into a new indication could strengthen Pfizer’s immunology growth outlook. Pfizer’s LITFULO Significantly Improved Facial and Total Body Repigmentation
• Positive Sentiment: Tilrekimig advances toward late-stage development: The company reported that its Phase 2 atopic dermatitis study met its primary endpoint, with significantly more patients achieving at least a 75% reduction in disease severity than those receiving placebo. Pfizer plans Phase 3 studies in atopic dermatitis and asthma, potentially adding a meaningful future immunology asset to its pipeline. Pfizer’s Tilrekimig Shows Significant Skin Clearance
• Positive Sentiment: Breast-cancer trial reaches a milestone: Pfizer provided an update on the TACTIVE-U Sub-Study C Phase 3 trial involving a breast-cancer combination. The update supports continued development of the oncology portfolio, although the available report does not provide enough efficacy or regulatory detail to quantify the commercial impact. Pfizer’s TACTIVE-U Breast Cancer Combo Trial Reaches Key Milestone
• Neutral Sentiment: Pipeline progress is important because Pfizer remains in transition: Analysts and financial commentary continue to highlight largely flat revenue, the decline in COVID-related sales and patent-loss pressure. Pfizer’s roughly 6% dividend yield may attract income investors, but future returns depend on successful launches and acquisitions translating into durable growth. Pfizer’s Dividend and Business Transition
• Negative Sentiment: Florida lawsuit adds legal overhang: Florida’s attorney general sued Pfizer and its chief executive over claims related to COVID-19 vaccine disclosures and risks. The allegations could create litigation costs, reputational damage and additional uncertainty around the company’s COVID-19 business.

Analysts Set New Price Targets

A number of research firms have commented on PFE. Guggenheim lowered their target price on shares of Pfizer from $35.00 to $31.00 and set a "buy" rating for the company in a report on Friday, August 7th. Weiss Ratings upgraded Pfizer from a "hold (c-)" rating to a "hold (c)" rating in a research report on Monday, August 31st. Wall Street Zen raised Pfizer from a "hold" rating to a "buy" rating in a research note on Sunday, September 13th. Cantor Fitzgerald reiterated a "neutral" rating and issued a $27.00 price objective on shares of Pfizer in a report on Monday, July 6th. Finally, BMO Capital Markets reduced their target price on Pfizer from $34.00 to $30.00 and set an "outperform" rating on the stock in a report on Monday, July 13th. One analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, fourteen have given a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of "Hold" and a consensus target price of $28.39.

Pfizer Stock Down 1.1%

The company has a market cap of $158.50 billion, a price-to-earnings ratio of 36.59, a price-to-earnings-growth ratio of 1.92 and a beta of 0.32. The company has a current ratio of 1.27, a quick ratio of 0.96 and a debt-to-equity ratio of 0.71. The firm's fifty day moving average price is $27.34 and its 200-day moving average price is $26.47.

Pfizer (NYSE:PFE - Get Free Report) last issued its quarterly earnings data on Tuesday, August 4th. The biopharmaceutical company reported $0.77 EPS for the quarter, topping the consensus estimate of $0.68 by $0.09. The business had revenue of $15.03 billion for the quarter, compared to the consensus estimate of $14.40 billion. Pfizer had a return on equity of 19.63% and a net margin of 6.80%.The firm's revenue was up 2.6% compared to the same quarter last year. During the same quarter last year, the business posted $0.78 EPS. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. Sell-side analysts predict that Pfizer Inc. will post 2.98 earnings per share for the current year.

Institutional Trading of Pfizer

A number of large investors have recently bought and sold shares of the business. Evolution Wealth Management Inc. increased its position in shares of Pfizer by 132.2% during the first quarter. Evolution Wealth Management Inc. now owns 994 shares of the biopharmaceutical company's stock worth $28,000 after acquiring an additional 566 shares in the last quarter. Keb Asset Management LLC acquired a new stake in shares of Pfizer in the 2nd quarter valued at about $26,000. Field & Main Bank bought a new stake in shares of Pfizer in the second quarter valued at about $27,000. Global Trust Asset Management LLC grew its holdings in shares of Pfizer by 126.7% during the first quarter. Global Trust Asset Management LLC now owns 1,163 shares of the biopharmaceutical company's stock worth $33,000 after buying an additional 650 shares in the last quarter. Finally, Bullseye Investment Management LLC acquired a new stake in Pfizer in the 2nd quarter valued at approximately $28,000. 68.36% of the stock is owned by institutional investors.

About Pfizer

Pfizer Inc NYSE: PFE is a global biopharmaceutical company that discovers, develops, manufactures and commercializes prescription medicines and vaccines. Its research and commercial activities focus on areas including oncology, inflammation and immunology, internal medicine, hospital care and vaccines.

The company's portfolio includes widely used products such as the Prevnar family of pneumococcal vaccines, Ibrance for certain breast cancers, Eliquis for preventing blood clots, Xeljanz for inflammatory conditions, and Vyndaqel for transthyretin amyloidosis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.